Deftos L J, O'Connor D T, Wilson C B, Fitzgerald P A
Department of Medicine, University of California-San Diego.
J Clin Endocrinol Metab. 1989 May;68(5):869-72. doi: 10.1210/jcem-68-5-869.
Chromogranin-A (CgA) has emerged as a serum and tissue marker for a number of endocrine tumors. We studied 15 patients with pituitary tumors to evaluate the clinical value of CgA as a serum and tissue marker for such tumors. One third of the patients had elevated serum CgA levels; 2 of these patients had nonsecreting pituitary tumors, and the other 3 had corticotroph adenomas. CgA-positive cells were detected in 9 of the 11 anterior pituitary tumors that were immunostained; in these 9 tumors at least half of the cells were CgA positive. We conclude that CgA production is common in pituitary tumors and that immunohistochemical studies for CgA may aid in their classification. In addition, serum CgA measurements may help to identify patients with pituitary tumors, especially those that do not secrete a known pituitary peptide.
嗜铬粒蛋白A（CgA）已成为多种内分泌肿瘤的血清和组织标志物。我们研究了15例垂体肿瘤患者，以评估CgA作为此类肿瘤血清和组织标志物的临床价值。三分之一的患者血清CgA水平升高；其中2例患者患有无分泌功能的垂体肿瘤，另外3例患有促肾上腺皮质激素腺瘤。在11例接受免疫染色的垂体前叶肿瘤中，9例检测到CgA阳性细胞；在这9例肿瘤中，至少一半的细胞CgA呈阳性。我们得出结论，CgA在垂体肿瘤中普遍存在，对CgA进行免疫组织化学研究可能有助于其分类。此外，检测血清CgA水平可能有助于识别垂体肿瘤患者，尤其是那些不分泌已知垂体肽的患者。
